Clinical Trials

1,314 enrolled

Prostatic Neoplasms

NCT02960022 2026-04-13

A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

900 enrolled

Prostatic Neoplasms

NCT05818683 2026-04-13

A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer

300 enrolled

Metastatic Castration-resistant Prostate Neoplasms

NCT05901649 2026-04-13

ArtemisPRO

Active not recruiting

504 enrolled

Metastatic Hormone-sensitive Prostate Cancer

NCT06863272 2026-04-13

IDeate-Prostate02

Phase 1/2 Recruiting

360 enrolled

Neoplasm Metastasis, Prostatic Neoplasms, Castration-Resistant

NCT07406282 2026-04-09

Double-DARE

Recruiting

1,400 enrolled

Prostatic Neoplasms

NCT06136624 2026-04-08

OMAHA-003

1,310 enrolled

Prostate Cancer Metastatic

NCT07287150 2026-04-08

InavoPC

100 enrolled

Metastatic Castration-Resistant Prostate Cancer

NCT03395197 2026-04-07

TALAPRO-2

1,054 enrolled 21 charts 2 FDA

mCRPC

NCT04821622 2026-04-07

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

599 enrolled

Prostatic Neoplasms

NCT05112965 2026-04-06

An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)

49 enrolled

Tumor-Agnostic

Neoplasms

NCT06120491 2026-04-03

EvoPAR-PR01

1,800 enrolled

Prostatic Neoplasms

NCT03899155 2026-04-01

Pan Tumor Rollover Study

1,500 enrolled

Tumor-Agnostic

Neoplasms

NCT04221542 2026-03-30

Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

479 enrolled

Bites and Stings, Prostatic Neoplasms

NCT07028853 2026-03-30

MEVPRO-3

1,000 enrolled

Prostatic Neoplasms

NCT04191096 2026-03-20

KEYNOTE-991

1,251 enrolled 15 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT05526248 2026-03-11

ARAMON

Phase 2 Completed

28 enrolled 14 charts

Biochemically Recurrent Prostate Cancer

NCT04179864 2026-03-10

CELLO-1

Phase 1/2 Terminated

102 enrolled 39 charts

Prostatic Neoplasms

NCT06691984 2026-03-06

Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

675 enrolled

Neoplasms, Prostatic Neoplasms

NCT06551324 2026-03-04

MEVPRO-1

600 enrolled

Prostatic Neoplasms, Recurrence

NCT07230106 2026-03-03

A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer

218 enrolled

Prostatic Neoplasms

NCT06257693 2026-02-27

Enzalutamide Implants (Enolen) in Patients With Prostate Cancer

56 enrolled

Prostate Adenocarcinoma

NCT05968599 2026-02-25

A Study to Learn About the Study Medicines Called Enzalutamide and Abiraterone in People With Metastatic Castration-resistant Prostate Cancer

Completed

2,731 enrolled 14 charts

Prostatic Neoplasms, Castration-Resistant

NCT05997615 2026-02-24

AMX-500

390 enrolled

Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT06855277 2026-02-24

AcTFirst

940 enrolled

Prostatic Neoplasms

NCT02861573 2026-02-17

KEYNOTE-365

Phase 1/2 Recruiting

1,200 enrolled

DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Metastatic Castration-Resistant Prostate Cancer

NCT05551117 2026-02-09

Tamarack

Phase 2 Terminated

192 enrolled 20 charts

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Carcinoma, Small Cell, Small Cell Lung Carcinoma, Prostatic Neoplasms, Castration-Resistant

NCT04729114 2026-02-04

A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

174 enrolled

Neoplasm Metastasis, Prostatic Neoplasms

NCT03768063 2026-01-29

IMbrella B

1,000 enrolled

Tumor-Agnostic

Neoplasms

NCT05701007 2026-01-29

Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland

Completed

1,083 enrolled 29 charts

Neoplasm Metastasis, Prostatic Neoplasms

NCT06764485 2026-01-28

rechARge

960 enrolled

1,401 enrolled 25 charts 1 FDA

Prostatic Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT02003924 2026-01-27

PROSPER

Phase 3 Completed

Prostatic Neoplasms

NCT03338790 2026-01-27

CheckMate 9KD

Phase 2 Completed

292 enrolled 21 charts